The studies were conducted by the Fraunhofer USA Center for Molecular Biotechnology (CMB), the contract research organization led by Vidadi Yusibov, through which BioTech executes its vaccine-related development activities. The results demonstrated preclinical efficacy of key HPV proteins produced by the AIPwLV technology, which induced specific immune responses and protected against HPV challenge infection.
HPV is the primary etiologic agent of cervical cancer, which represents the third leading cause of cancer-related death among women worldwide. The reported results support the possibility of producing prophylactic and therapeutic HPV vaccines using the AIPwLV technology.
The studies also demonstrated that other vaccine candidates made using the AIPwLV technology induced specific immune responses and conferred complete protection against lethal doses of anthrax and plague, two substances considered as likely bioterrorism agents.
Dr Yusibov, the executive director of CMB, said: “It offers rapid, unparalleled scalability of vaccine production and cost efficiency, addressing the principal concerns affecting current methods of vaccine production, particularly where large scale or rapid inoculation is desired.”